The table below shows Viridian Therapeutics, Inc.DE's income statement by quarter, as reported in the company's quarterly filings. All figures are in US dollars; negative values appear in red.
Line item
Q1 2026
Q3 2025
Q2 2025
Q1 2025
Q3 2024
Q2 2024
Revenue
$141.00K
$70.57M
$75.00K
$72.00K
$86.00K
$72.00K
Cost of revenue
-
-
-
-
-
-
Gross profit
-
-
-
-
-
-
R&D
-
-
-
-
-
-
SG&A
VRDN annual revenue (10-K history)
Viridian Therapeutics, Inc.DE reported annual revenue of $70.85M for fiscal year 2025. That is up 23359.9% from $302.00K in fiscal 2024. Over the 10 fiscal years shown, annual revenue grew from $3.48M (FY 2016) to $70.85M. Figures come from the company's audited annual reports as filed with the SEC.